Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser

No particular regimen is considered standard therapy for widespread metastatic melanoma, although surgery is the primary choice for regional nodal metastases. Systemic interleukin-2 (IL-2) is an effective immunotherapy for melanoma, but standard doses are associated with severe toxicity. We report a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Michael Z., Brewer, Jerry D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934508/
https://www.ncbi.nlm.nih.gov/pubmed/27429133
http://dx.doi.org/10.3390/healthcare1010096
_version_ 1782441347215523840
author Wang, Michael Z.
Brewer, Jerry D.
author_facet Wang, Michael Z.
Brewer, Jerry D.
author_sort Wang, Michael Z.
collection PubMed
description No particular regimen is considered standard therapy for widespread metastatic melanoma, although surgery is the primary choice for regional nodal metastases. Systemic interleukin-2 (IL-2) is an effective immunotherapy for melanoma, but standard doses are associated with severe toxicity. We report a patient who was treated with intralesional low-dose IL-2 and V-beam pulsed dye laser for the treatment of scalp melanoma metastases. This treatment resulted in rapid regression of metastatic tumors with limited adverse effects.
format Online
Article
Text
id pubmed-4934508
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-49345082016-07-12 Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser Wang, Michael Z. Brewer, Jerry D. Healthcare (Basel) Case Report No particular regimen is considered standard therapy for widespread metastatic melanoma, although surgery is the primary choice for regional nodal metastases. Systemic interleukin-2 (IL-2) is an effective immunotherapy for melanoma, but standard doses are associated with severe toxicity. We report a patient who was treated with intralesional low-dose IL-2 and V-beam pulsed dye laser for the treatment of scalp melanoma metastases. This treatment resulted in rapid regression of metastatic tumors with limited adverse effects. MDPI 2013-10-25 /pmc/articles/PMC4934508/ /pubmed/27429133 http://dx.doi.org/10.3390/healthcare1010096 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Case Report
Wang, Michael Z.
Brewer, Jerry D.
Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser
title Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser
title_full Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser
title_fullStr Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser
title_full_unstemmed Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser
title_short Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser
title_sort scalp in-transit metastatic melanoma treated with interleukin-2 and pulsed dye laser
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934508/
https://www.ncbi.nlm.nih.gov/pubmed/27429133
http://dx.doi.org/10.3390/healthcare1010096
work_keys_str_mv AT wangmichaelz scalpintransitmetastaticmelanomatreatedwithinterleukin2andpulseddyelaser
AT brewerjerryd scalpintransitmetastaticmelanomatreatedwithinterleukin2andpulseddyelaser

Ejemplares similares